BridgeBio Pharma (BBIO) Gains from Investment Securities (2018 - 2026)

BridgeBio Pharma has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $4.1 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $4.1 million, up 19300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 733.43% YoY), and the FY2025 annual result was $14.2 million, up 1302.72% from the prior year.
• Gains from Investment Securities came in at $4.1 million for Q1 2026 at BridgeBio Pharma, down from $7.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $10.2 million in Q2 2022 to a low of -$5.2 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $87584.0 (2023), against an average of $1.1 million.
• Across the five-year window, Gains from Investment Securities tumbled 3958.69% in 2022 and surged 19300.0% in 2026, its largest moves.
• BridgeBio Pharma's Gains from Investment Securities stood at -$3.6 million in 2022, then jumped by 170.56% to $2.6 million in 2023, then tumbled by 303.01% to -$5.2 million in 2024, then surged by 243.24% to $7.4 million in 2025, then tumbled by 45.17% to $4.1 million in 2026.
• The last three Gains from Investment Securities figures came in at $4.1 million (Q1 2026), $7.4 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.